Heterotrimeric G protein

Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update

Retrieved on: 
Friday, April 5, 2024
TME, Development, FAP, Doctor of Philosophy, Patient, Doxorubicin, Tumor microenvironment, Royal Marsden Hospital, MD, AACR, Research and development, Institute of Cancer Research, Poster, Heterotrimeric G protein, BST, AIM, Fine chemical

Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.

Key Points: 
  • Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.
  • A copy of the abstract will be available on Avacta’s website at: https://avacta.com/about/scientific-resources/ .
  • Christina Coughlin will provide a video presentation overview examining the data presented in the poster.
  • Alastair Smith, Avacta Chief Executive Officer, will also be hosting a webinar on Wednesday, April 10 2024 at 5.30pm BST to discuss the data.

Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024

Retrieved on: 
Tuesday, March 5, 2024
Institute of Cancer Research, FAP, Royal Marsden Hospital, Doctor of Philosophy, Heterotrimeric G protein, MD, TME, AACR, AIM, Tumor microenvironment, Patient, Poster, Fine chemical

Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024

Key Points: 
  • Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024
    Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces updated clinical data from the First-in-Human Phase 1 trial of the peptide drug conjugate, AVA6000 will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April 2024.
  • The results will be presented in the Phase 1 Clinical Trials 2 Poster Session on April 9, 2024 as detailed below.
  • Title: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
    First Author: Udai Banerji, MD, PhD, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust
    For further information from Avacta Group plc, please contact:

ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data

Retrieved on: 
Wednesday, December 13, 2023
Quality of life, UPS, Neoplasm, Tumor microenvironment, Male, IMC, Heterotrimeric G protein, FAP, AIM, Cancer, GMT, Toxicity, Enzyme, Doxorubicin, Patient, Safety, Medical imaging

Cohort 7, the final cohort in the three-weekly dose escalation safety study of AVA6000, has completed enrolment and is ongoing

Key Points: 
  • Cohort 7, the final cohort in the three-weekly dose escalation safety study of AVA6000, has completed enrolment and is ongoing
    Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to provide detailed pre-clinical, clinical and pharmacokinetic data from the Phase 1a dose escalation study of its lead pre|CISIONTM programme, AVA6000, a tumour activated form of doxorubicin.
  • The key conclusions drawn from the data for AVA6000 to date are:
    The pre|CISIONTM platform targets the release of a chemotherapy to the tumour as intended.
  • A maximum tolerated dose has not been reached in the three-weekly dose escalation study despite dosing approximately 3.5x the normal level of doxorubicin in the highest and final dose cohort in this part of the Phase 1a study.
  • Given the favourable safety data from the three-weekly dosing study, a fortnightly dosing study, which is now screening patients with high FAP levels in the United States, will assist in optimising the schedule and dose for a potentially pivotal Phase 2 study in 2024.

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Retrieved on: 
Monday, December 4, 2023
Google Images, National Cancer Institute, Neoplasm, Medicine, Lung, PET/CT, Cancer, PET, Trial of the century, Heterotrimeric G protein, FAP, University, Prostate, INT, Patient, Diagnosis, Safety, Radiopharmaceutical, Skin, Medical imaging

Under the agreement, the Philogen Group is conducting a Phase 1 clinical study to evaluate the safety and dosimetry of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) in patients with solid tumors.

Key Points: 
  • Under the agreement, the Philogen Group is conducting a Phase 1 clinical study to evaluate the safety and dosimetry of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) in patients with solid tumors.
  • The agreement provides Blue Earth Diagnostics rights to develop and commercialize 68Ga-OncoFAP worldwide.
  • The Philogen Group has a Phase I clinical trial (called FAPrimo) underway in Europe to evaluate the safety and dosimetry of 68Ga-OncoFAP in patients with solid tumors.
  • The first three enrolled patients in the trial were imaged in November 2023 at the National Cancer Institute of Milan (INT).

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Retrieved on: 
Monday, December 4, 2023
Oncology, Health, Clinical Trials, Radiology, Pharmaceutical, Biotechnology, Lung, Prostate, Safety, Bone sarcoma, PET/CT, Heterotrimeric G protein, National Cancer Institute, Jaden Philogene, Google Images, Patient, Multimedia, Radiopharmaceutical, Medicine, FAP, Cancer, University, Trial of the century, Diagnosis, INT, PET, Skin, Neoplasm, Medical imaging, Bracco, Leonardo S.p.A.

The collaboration encompasses the development of OncoFAP, a proprietary, small organic ligand with ultra-high affinity to Fibroblast Activation Protein (FAP), for applications in the diagnostic imaging of solid tumors.

Key Points: 
  • The collaboration encompasses the development of OncoFAP, a proprietary, small organic ligand with ultra-high affinity to Fibroblast Activation Protein (FAP), for applications in the diagnostic imaging of solid tumors.
  • Under the agreement, the Philogen Group is conducting a Phase 1 clinical study to evaluate the safety and dosimetry of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) in patients with solid tumors.
  • The agreement provides Blue Earth Diagnostics rights to develop and commercialize 68Ga-OncoFAP worldwide.
  • The first three enrolled patients in the trial were imaged in November 2023 at the National Cancer Institute of Milan (INT).

NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress

Retrieved on: 
Tuesday, September 5, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, NETS, 18F, Half-life, EANM, PSMA, Survival, Cancer, Pharmacokinetics, University Hospital of Basel, FAP, Heterotrimeric G protein, Nuclear medicine, Radiopharmaceutical, Doctor of Philosophy, University Hospital of Zürich, Glomus tumor, European Association of Nuclear Medicine, Patient, PET/CT, Entrepreneurship, European Association for the Study of the Liver, Prostate cancer, Medical imaging

NUCLIDIUM today announced the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours (KaliosTM), neuroendocrine tumours (TraceNETTM) and prostate cancer (NuriProTM) at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM), 09-13 September 2023.

Key Points: 
  • NUCLIDIUM today announced the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours (KaliosTM), neuroendocrine tumours (TraceNETTM) and prostate cancer (NuriProTM) at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM), 09-13 September 2023.
  • The data, presented in two oral presentations and a poster presentation, support the advancement of these three programs into clinical translation.
  • The programs are part of NUCLIDIUM’s comprehensive pipeline of copper-based radiotheranostics based on its flexible CuTraceTM platform.
  • The positive pre-clinical data for the diagnostic candidates from three of our programs and the preparation for clinical translation represent an important step for NUCLIDIUM.

Ferronova and Purdue Research Foundation (PRF) Sign Licensing Agreement for Use of Fibroblast Activation Protein (FAP) Inhibitor in Radiotherapy

Retrieved on: 
Wednesday, August 23, 2023
Clinical Trials, Philanthropy, Biotechnology, Radiology, Fund Raising, General Health, Pharmaceutical, Health, Foundation, Oncology, Proton, Royal Adelaide Hospital, Pancreatic cancer, Purdue Research Park, Glioblastoma, University, Partnership, Central nervous system, Drug discovery, SPION, SAHMRI, Survival, South Australian Health and Medical Research Institute, FAP, Heterotrimeric G protein, Attention, Cell, University of South Australia, CAF, Radiation therapy, Purdue University College of Pharmacy, Associate, PRF, MRI, Magnetic resonance imaging, Patient, RAH, Purdue University, Cancer, Proton therapy, SA, News, Fibroblast, Prostate cancer, Medical imaging, Pharmaceutical industry, Chemistry, Research

Australian biotech company Ferronova announced today that it has signed a licensing agreement with the Purdue Research Foundation (PRF) for the application of PRF’s patented Fibroblast Activation Protein (FAP) inhibitor in magnetic resonance imaging (MRI) and MRI-guided therapies.

Key Points: 
  • Australian biotech company Ferronova announced today that it has signed a licensing agreement with the Purdue Research Foundation (PRF) for the application of PRF’s patented Fibroblast Activation Protein (FAP) inhibitor in magnetic resonance imaging (MRI) and MRI-guided therapies.
  • The licensing agreement will bring together Ferronova’s patented FerroTrace® platform, a super-paramagnetic iron-oxide nanoparticle (SPION) formulation, and PRF’s patented FAP inhibitor in a combination to be applied in targeted radiotherapy of difficult cancers with complicated treatment margins such as glioblastoma, prostate cancer and pancreatic cancer.
  • “Purdue researchers are the driving force behind world changing innovations, and our partnership with Ferronova serves as yet another testament to our dedication to partnering with companies that can improve the world and save lives with Purdue technologies,” said Brooke Beier, senior vice president of Purdue Innovates.
  • “We are hopeful that this collaboration will change that, and in future, have a positive impact on the management of patients with this tragic disease.”

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors

Retrieved on: 
Friday, May 12, 2023
TNBC, Triple-negative breast cancer, Euronext Growth, TAA, Neoplasm, Gene editing, UCAR, Cancer, Cancer-associated fibroblast, Breast, FAP, Heterotrimeric G protein, CAF, Malignancy, Mesothelin, CAR, Patient, Extracellular matrix, TME, ISCB Senior Scientist Award, Mesothelioma, Cytokine, Tumor microenvironment, Vaccine, Medical imaging, Cellectis

Adoptive cell therapy based on chimeric antigen receptor-engineered T (CAR-T) cells has proven to be lifesaving for many cancer patients.

Key Points: 
  • Adoptive cell therapy based on chimeric antigen receptor-engineered T (CAR-T) cells has proven to be lifesaving for many cancer patients.
  • However, its therapeutic efficacy has so far been restricted to only a few malignancies, with solid tumors proving to be especially recalcitrant to efficient therapy.
  • Poor intra-tumor infiltration by T cells and T cell dysfunction due to a desmoplastic, immunosuppressive microenvironment are key barriers for CAR T-cell success against solid tumors.
  • CAF depletion in stroma rich solid tumors can thus provide an opportunity to convert immune evasive tumors susceptible to tumor-antigen CAR T-cell cytotoxicity.

Philochem AG, Seibersdorf Labor GmbH and Isotopia announce supply, development, and manufacturing agreements

Retrieved on: 
Tuesday, December 13, 2022
Molecule, Isotopia Festival, Therapy, Heterotrimeric G protein, Precision medicine, Cytokine, Business, Jaden Philogene-Bidace, Doctor of Philosophy, Nuclear pharmacy, Small molecule, Patient, Isotope, GMP, Disease, Neoplasm, CMO, Antibody, Molecular imaging, FAP, Radiopharmaceutical, Business development, Medical imaging, Pharmaceutical industry, Mercury

OTELFINGEN, Switzerland, SEIBERSDORF, Austria and PETAH TIKVA, Israel, Dec. 13, 2022 /PRNewswire/ -- Philochem, Seibersdorf Laboratories and Isotopia Molecular Imaging have today announced that they have signed agreements that will help advance the next generation of Radiopharmaceutical Therapies for cancer treatment.

Key Points: 
  • Under these agreements, Isotopia will supply high quality 177 Lu-n.c.a to Seibersdorf Laboratories for the purpose of conducting development and manufacturing activities for Philochem's proprietary therapeutic candidate, OncoFAP-23.
  • Sammuele Cazzamalli, PhD, Head of Small Molecule Therapeutics at Philochem commented: " We are delighted to start working with Isotopia and Seibersdorf Laboratories on the manufacturing of our Targeted Radioligand Therapeutics.
  • The experienced Isotopia team, together with its nuclear pharmacy, cyclotron facility, 177Lu production site and sterile manufacturing plant, are a well-established platform for manufacturing and collaborations.
  • Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy.

Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries

Retrieved on: 
Monday, November 7, 2022
Heterotrimeric G protein, Protein, DNA, Research, Blood, Tissue, Antibody, Mouse, Intellectual property, Neoplasm, Group, FAP, Chemical library, Disease, Antigen, DEL, Ligand, Cancer, Pharmaceutical industry, Vaccine, Jaden Philogene-Bidace

The study, conducted by scientists at Philochem AG, the wholly-owned Swiss subsidiary company of Philogen, shows how Philochems DNA Encoded Chemical Libraries can be applied to generate novel ultra-potent small molecule ligands for tumor targeting applications.

Key Points: 
  • The study, conducted by scientists at Philochem AG, the wholly-owned Swiss subsidiary company of Philogen, shows how Philochems DNA Encoded Chemical Libraries can be applied to generate novel ultra-potent small molecule ligands for tumor targeting applications.
  • The application of Philochems affinity-maturation DNA-encoded chemical libraries (DEL), based on three series of 50,730 propargylglycine derivatives, have enabled the identification of picomolar FAP-inhibitors.
  • Using these ligands Philogen is developing OncoFAP binders that have shown very rapid and selective accumulation to tumor lesions.
  • These ligands - human monoclonal antibodies or small organic molecules - are identified using Antibody Phage Display Libraries and DNA-Encoded Chemical Library technologies.